Open AccessCost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective
Author(s) -
Xiao Jun Wang,
Yi-Ho Wang,
Matthew Jian Chun Ong,
Christina Gkitzia,
Shui Yen Soh,
William Ying Khee Hwang
Publication year - 2022
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s355557
Subject(s) - medicine , perspective (graphical) , lymphoblastic leukemia , refractory (planetary science) , health care , intensive care medicine , pediatrics , oncology , leukemia , immunology , computer science , biology , artificial intelligence , astrobiology , economics , economic growth
Children and young adults with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) have poor survival due to ineffective therapy options. The newly approved chimeric antigen receptor T-cell (CAR-T) therapy, tisagenlecleucel, has demonstrated improved survival but at a high up-front cost. The study aims to evaluate the cost-effectiveness and budget impact of tisagenlecleucel versus salvage chemotherapy regimen (SCR) or blinatumomab (BLN) for the treatment of pediatric and young adult patients with relapsed/refractory B-cell ALL from the Singapore healthcare system perspective.